116 results
8-K
EX-99.1
ACET
Adicet Bio Inc
14 May 24
Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates
4:03pm
:
Research and Development (R&D) Expenses: R&D expenses were $23.9 million for the three months ended March 31, 2024, compared to $26.8 million during … manufacturing organizations (CDMOs) and other externally conducted research and development.
General and Administrative (G&A) Expenses: G&A expenses were
DEFR14A
ACET
Adicet Bio Inc
26 Apr 24
Revised proxy
4:13pm
. From December 2007 to June 2010, she served as Executive Vice President, Head of Research and Development at Agensys Inc. (Agensys), an affiliate … Development and Chief Scientific Officer and led its research, development, clinical and corporate development operations from January 1999 to December
PRE 14A
ACET
Adicet Bio Inc
12 Apr 24
Preliminary proxy
5:23pm
Vice President, Head of Research and Development at Agensys Inc. (Agensys), an affiliate of Astellas Pharma, Inc. (Astellas). Before Agensys … Development Corporation from 2017 to 2022 and on the board of Yeda Research and Development Co. Ltd. From 2019 to 2023. Dr. Jakobovits previously
424B5
8hwsc uo1s7bxz
22 Mar 24
Prospectus supplement for primary offering
4:12pm
8-K
EX-99.1
oarj lwzj4y
19 Mar 24
Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
4:13pm
424B5
pd21btrav
24 Jan 24
Prospectus supplement for primary offering
4:32pm
424B5
x0dbs6 icblcrf5q
22 Jan 24
Prospectus supplement for primary offering
4:30pm
8-K
EX-99.1
f7apt
4 Jan 24
Adicet Provides Corporate Update and Highlights Strategic Priorities for 2024
7:17am
8-K
EX-99.1
cwslvsbveal c3wdia
8 Nov 23
Adicet Reports Third Quarter 2023 Financial Results and Provides Business Updates
4:12pm
8-K
EX-99.1
xna8k6z53zdx7x78ofi
9 Aug 23
Adicet Reports Second Quarter 2023 Financial Results and Provides Business Updates
4:17pm
8-K
EX-99.1
geryy
9 May 23
Adicet Reports First Quarter 2023 Financial Results and Provides Business Updates
4:14pm
8-K
701i06lvhvjnzn9o
10 Nov 22
Regulation FD Disclosure
5:09pm
424B5
ar6lmu2pdhk cx4
8 Nov 22
Prospectus supplement for primary offering
5:23pm